证券代码：603014 证券简称：威高血净 公告编号：2025-021 山东威高血液净化制品股份有限公司 薪酬与考核委员会关于公司 2025 年限制性股票 激励计划激励对象名单的核查意见及公示情况说明 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东威高血液净化制品股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日召开第二届董事会第十三次会议，审议通过了《关于公司 2025 年限制性股票 激励计划（草案）及其摘要的议案》（以下简称"本激励计划"）等议案，上述议 案已经第二届董事会薪酬与考核委员会 2025 年第二次会议审议通过。公司已于 2025 年 8 月 28 日在上海证券交易所网站（www.sse.com.cn）上披露了相关公告。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《上市 公司信息披露管理办法》等法律、法规及规范性文件的要求，公司对本激励计划 激励对象的姓名和职务在公司内部进行了公示，公司董事会薪酬与考核委员会结 合公示情况对激励对象进行了核查，相关公示情况及核查情况如下： ...

Core Viewpoint - Weigao Blood Products (603014) experienced a decline of 1.55% in stock price, with a trading volume turnover rate of 34.24% and a total transaction amount of 559 million yuan, indicating significant trading activity and potential investor concern [2]. Trading Activity - The stock was listed on the Shanghai Stock Exchange due to its high turnover rate, with a net selling amount of 18.46 million yuan from brokerage seats [2]. - The top five brokerage seats accounted for a total transaction amount of 212 million yuan, with buying transactions amounting to 96.58 million yuan and selling transactions totaling 115 million yuan, resulting in a net selling of 18.46 million yuan [2]. - The largest buying brokerage was GF Securities, which purchased 31.49 million yuan, while the largest selling brokerage was Huaxin Securities, which sold 34.16 million yuan [2]. Fund Flow - The stock saw a net inflow of 50.76 million yuan from major funds, with a significant inflow of 11.35 million yuan from large orders and 39.41 million yuan from regular orders. Over the past five days, the net inflow of major funds reached 171 million yuan [2]. Financial Performance - According to the semi-annual report released on August 28, the company achieved a revenue of 1.765 billion yuan in the first half of the year, representing a year-on-year growth of 8.52%. The net profit for the same period was 220 million yuan, reflecting a year-on-year increase of 10.11% [2].

Company Overview - Weigao Blood Purification Products Co., Ltd. is located in Weihai, Shandong Province, established on December 27, 2004, and listed on May 19, 2025. The company specializes in the research, production, and sales of medical products for blood purification [1][2]. Financial Performance - For the first half of 2025, Weigao Blood Purification achieved operating revenue of 1.765 billion yuan, representing a year-on-year growth of 8.52%. The net profit attributable to the parent company was 220 million yuan, with a year-on-year increase of 10.11% [2]. Stock Performance - As of September 3, Weigao Blood Purification's stock price increased by 2.04%, reaching 43.53 yuan per share, with a trading volume of 307 million yuan and a turnover rate of 18.75%. The total market capitalization is 17.908 billion yuan [1]. - Year-to-date, the stock price has risen by 5.12%, with a 12.25% increase over the last five trading days, a 9.40% increase over the last 20 days, and an 18.29% increase over the last 60 days [1]. Market Activity - The net inflow of main funds was 28.5053 million yuan, with large orders accounting for 28.07% of total purchases and 17.82% of total sales. The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on September 2, where it recorded a net buy of -16.0277 million yuan [1]. Shareholder Information - As of June 30, the number of shareholders for Weigao Blood Purification was 31,400, a decrease of 47.45% from the previous period. The average number of circulating shares per person increased by 90.29% to 1,213 shares [2]. Industry Classification - Weigao Blood Purification is classified under the pharmaceutical and biological industry, specifically in the medical device and medical consumables sector. It is part of several concept sectors, including medical devices, mid-cap stocks, and newly listed stocks [2]. Revenue Composition - The company's main business revenue composition is as follows: consumables account for 77.55%, equipment for 18.25%, and other supplementary products for 2.35% [1].

Meeting Overview - The company is holding a temporary shareholders' meeting to discuss various proposals, including the 2025 restricted stock incentive plan [1][2] - The meeting will follow specific procedures to ensure order and efficiency, with provisions for shareholder participation and questioning [1][2] Agenda Items - Proposal 1: Discussion on the company's 2025 interim dividend plan, which aims to enhance shareholder returns [2][3] - Proposal 2: Review of the 2025 restricted stock incentive plan draft and its summary [2][6] - Proposal 3: Examination of the implementation assessment management measures for the 2025 restricted stock incentive plan [2][7] - Proposal 4: Authorization for the board to handle matters related to the 2025 restricted stock incentive plan [2][9] - Proposal 5: Cancellation of the supervisory board and amendments to the company's business scope and articles of association [2][11] - Proposal 6: Development and revision of certain governance systems [2][12] - Proposal 7: Review of candidates for the second board's independent directors and their annual allowances [2][13] Dividend Proposal - The company proposes a mid-year dividend not exceeding 30% of the net profit attributable to shareholders for 2025 [3][4] - The proposed cash dividend is 1.6 yuan per 10 shares, totaling approximately 65.82 million yuan, which represents 29.89% of the net profit for the first half of 2025 [5][6] Restricted Stock Incentive Plan - The company aims to implement a restricted stock incentive plan to attract and retain talent, aligning the interests of shareholders, the company, and core team members [6][7] - The plan's details will be disclosed on August 28, 2025, and it has been approved by the board and supervisory committee [7][9] Governance Changes - The company plans to abolish the supervisory board and amend its articles of association to comply with updated regulations [11] - Several governance systems will be revised to enhance operational standards and compliance with regulatory requirements [12] Independent Director Nomination - The company proposes to nominate Zhang Zhenhua as an independent director, with an annual allowance of 150,000 yuan [13][14] - Zhang Zhenhua meets all qualifications and independence criteria as per relevant regulations [14][15]

山东威高血液净化制品股份有限公司 2025年第一次临时股东大会 会议资料 证券代码:603014 2025年9月 0 资料目录 | 2025年第一次临时股东大会会议须知 2 | | --- | | 2025年第一次临时股东大会议程 3 | | 议案一：关于公司2025年度中期分红的议案 5 | | 议案二：关于公司《2025年限制性股票激励计划（草案）》及其摘要的议案 7 | | 议案三：关于公司《2025年限制性股票激励计划实施考核管理办法》的议案 8 | | 议案四：关于提请公司股东大会授权董事会办理2025年限制性股票激励计划相关事宜的议案.. 9 | | 议案五：关于取消监事会、变更公司经营范围暨修改公司章程的议案 11 | | 议案六：关于制定及修订公司部分治理制度的议案 12 | | 议案七：关于审议第二届董事会独立董事候选人及其年度津贴的议案 13 | 1 2025年第一次临时股东大会会议须知 为维护广大股东的合法权益，确保本次临时股东大会的正常秩序和议事效率， 山东威高血液净化制品股份有限公司（以下简称"公司"）根据《中华人民共和国 公司法》《中华人民共和国证券法》、本公司《公司章程》以及《上 ...

威高血净(603014)今日上涨4.02%，全天换手率46.10%，成交额7.70亿元，振幅7.92%。龙虎榜数据显 示，营业部席位合计净卖出1602.77万元。 上交所公开信息显示，当日该股因日换手率达46.10%上榜，营业部席位合计净卖出1602.77万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交2.63亿元，其中，买入成交额为1.23亿 元，卖出成交额为1.39亿元，合计净卖出1602.77万元。 具体来看，今日上榜营业部中，第一大买入营业部为华鑫证券有限责任公司上海云锦路证券营业部，买 入金额为3566.01万元，第一大卖出营业部为中信证券股份有限公司深圳福田金田路证券营业部，卖出 金额为6006.84万元。 资金流向方面，今日该股主力资金净流入1.01亿元，其中，特大单净流入1.07亿元，大单资金净流出 592.20万元。近5日主力资金净流入1.21亿元。 8月28日公司发布的半年报数据显示，上半年公司共实现营业收入17.65亿元，同比增长8.52%，实现净 利润2.20亿元，同比增长10.11%。（数据宝） 威高血净9月2日交易公开信息 | 买/ 卖 | 会员营业部名称 | 买入 ...

Group 1 - The medical device sector experienced a decline of 1.78% on September 2, with Jimin Health leading the losses [1] - The Shanghai Composite Index closed at 3858.13, down 0.45%, while the Shenzhen Component Index closed at 12553.84, down 2.14% [1] - Notable gainers in the medical device sector included Wende Biological, which rose by 7.61% to a closing price of 25.58, and Jinhao Medical, which increased by 6.66% to 29.48 [1] Group 2 - Jimin Health saw a significant drop of 10.02%, closing at 11.40, with a trading volume of 1.0859 million shares and a transaction value of 1.331 billion [2] - Other notable decliners included Rejing Biological, which fell by 8.72% to 186.79, and Yikang Haosheng, which decreased by 7.71% to 34.24 [2] - The medical device sector experienced a net outflow of 1.23 billion from major funds, while retail investors contributed a net inflow of 1.011 billion [2]

Market Performance - The medical device sector increased by 1.87% on September 1, with Yirui Biological leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Top Gainers in Medical Device Sector - Yirui Biological (300942) closed at 13.82, up 13.56% with a trading volume of 263,400 shares and a transaction value of 350 million [1] - Jimin Health (603222) closed at 12.67, up 9.98% with a trading volume of 1,050,500 shares [1] - Hualan Biological (301093) closed at 37.16, up 9.55% with a trading volume of 123,900 shares [1] - Huatai Medical (688617) closed at 305.49, up 7.43% with a trading volume of 30,100 shares [1] - United Imaging Healthcare (688271) closed at 152.10, up 7.26% with a trading volume of 147,200 shares [1] Top Losers in Medical Device Sector - Toukeng Life (300642) closed at 28.50, down 7.71% with a trading volume of 234,300 shares [2] - Blue Sail Medical (002382) closed at 5.99, down 3.07% with a trading volume of 288,400 shares [2] - Wuzhou Medical (301234) closed at 43.30, down 2.48% with a trading volume of 20,800 shares [2] Capital Flow Analysis - The medical device sector saw a net inflow of 68.08 million from institutional investors, while retail investors contributed a net inflow of 14.9 million [2] - The sector experienced a net outflow of 217 million from speculative funds [2] Individual Stock Capital Flow - Mindray Medical (300760) had a net inflow of 90.24 million from institutional investors, while it faced a net outflow of 128 million from speculative funds [3] - United Imaging Healthcare (688271) saw a net inflow of 87.93 million from institutional investors, with a net outflow of 130 million from speculative funds [3] - Jimin Health (603222) experienced a net inflow of 79.82 million from institutional investors, but a net outflow of 49.23 million from speculative funds [3]

Core Viewpoint - Weigao Blood Purification (603014.SH) reported a positive performance in the first half of 2025, with revenue and net profit showing growth compared to the previous year [1] Financial Performance - The company's revenue for the first half of 2025 was approximately 1.765 billion yuan, representing a year-on-year increase of 8.52% [1] - The net profit attributable to shareholders was around 220 million yuan, reflecting a year-on-year growth of 10.11% [1] - Research and development expenses amounted to approximately 70.18 million yuan, accounting for 3.98% of total revenue [1] Dividend Distribution - The company plans to distribute a cash dividend of 1.6 yuan (including tax) for every 10 shares to all shareholders [1] Product and Market Presence - As of the end of the reporting period, Weigao Blood Purification held 16 Class III medical device product registration certificates [1] - The company's products are sold across 31 provinces, municipalities, and autonomous regions in China, reaching over 6,000 medical institutions, including more than 1,000 tertiary hospitals [1]

Core Viewpoint - Weigao Blood Products (603014.SH) reported a positive financial performance in the first half of 2025, indicating growth in both revenue and net profit [1] Financial Performance - The company achieved a total operating revenue of 1.765 billion yuan, representing a year-on-year increase of 8.52% [1] - The net profit attributable to shareholders reached 220 million yuan, reflecting a year-on-year growth of 10.11% [1] - Basic earnings per share were reported at 0.58 yuan [1] Dividend Distribution - The company proposed a cash dividend of 1.6 yuan (including tax) for every 10 shares to all shareholders [1]